Carmine Carriero

Carmine Carriero

Auto-generated profile, based on publicly available information

Carmine Carriero

Univ Bari, Dept Gynecol & Obstet, Bari, Italy

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Gynecologic Oncology
Verified
Journal Article
Closed access
GCGennaro Cormio
Gennaro Cormio
MCMariateresa Capotorto
Mariateresa Capotorto
GVGiovanni Di Vagno
Giovanni Di Vagno
ACAmbrogio Cazzolla
Ambrogio Cazzolla
CCCarmine Carriero
Carmine Carriero
LSLuigi Selvaggi
Luigi Selvaggi

1 August 2005 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
LNLuigi Nappi
Luigi Nappi
CCC. Carriero
C. Carriero
SBStefano Bettocchi
Stefano Bettocchi
JHJ. Herrero
J. Herrero
Antonella VimercatiAntonella Vimercati
Antonella Vimercati
GPG. Putignano
G. Putignano

1 February 2008 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
GLGiuseppe Loverro
Giuseppe Loverro
CCCarmine Carriero
Carmine Carriero
ARA. Cristina Rossi
A. Cristina Rossi
GPGiuseppe Putignano
Giuseppe Putignano
VNVittorio Nicolardi
Vittorio Nicolardi
LSLuigi Selvaggi
Luigi Selvaggi

1 August 2003 in Maturitas
Verified
Journal Article
Closed access
LCL.M. Chiechi
L.M. Chiechi
GPG. Putignano
G. Putignano
VGV. Guerra
V. Guerra
MSM.P. Schiavelli
M.P. Schiavelli
ACA.M. Cisternino
A.M. Cisternino
CCC. Carriero
C. Carriero

1 May 2010 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
GCGennaro Cormio
Gennaro Cormio
Vera LoizziVera Loizzi
Vera Loizzi
CCC. Carriero
C. Carriero
ACA. Cazzolla
A. Cazzolla
GPG. Putignano
G. Putignano
LSL. Selvaggi
L. Selvaggi
The aim of the study was to investigate the management and outcome of inguinal recurrence in vulvar carcinoma patients. A retrospective chart review was conducted on 140 patients with squamous cell carcinoma of the vulva treated between 1994 and 2006. Twenty-one patients were found to have groin recurrence. Median interval between primary treatment of vulvar cancer and groin recurrence was 7 months. Three patients refused any treatment, 3 received chemotherapy, 2 inguino-pelvic radiotherapy and 13 had resection of the groin recurrence. After surgery seven patients received irradiation of the groin and pelvis, and three patients received chemotherapy. One patient died following surgery; 19 patients died of disease with the median survival after diagnosis of inguinal recurrence of 9 months. Only one patient is alive without evidence of disease at 60 months following surgery. In univariate analysis, stage and grade at diagnosis, age and performance status at the recurrent disease, and the extent of residual tumour after resection of groin recurrence were predictors for survival. Groin recurrences from vulvar carcinoma carry a poor prognosis. Multi-modal treatment may result in a palliation of the disease, and a very limited number of patients have long-term survival.

16 November 2009 in Oncology
Verified
Journal Article
Closed access
GCGennaro Cormio
Gennaro Cormio
Vera LoizziVera Loizzi
Vera Loizzi
FGFrancesca Gissi
Francesca Gissi
GSGiuseppe Serrati
Giuseppe Serrati
MPMariantonietta Panzarino
Mariantonietta Panzarino
LSLuigi Selvaggi
Luigi Selvaggi
Purpose: To evaluate the activity and toxicity of the combination of cisplatin and vinorelbine in patients with recurrent carcinoma of the vulva that has not been previously treated with chemotherapy. Patients and Methods: Sixteen women with a median age of 65 years (range 43–79) with recurrent vulvar carcinoma were enrolled in the study. Nine patients had local recurrent disease (perineum, vagina and/or vulva), whereas 7 had disease in the groin; 9 patients had received prior radiotherapy. Cisplatin was administered intravenously on day 1 and vinorelbine was given on day 1 immediately after cisplatin and on day 8. Results: A total of 68 cycles of chemotherapy were administered. Fifteen women were assessed for response. Objective responses were recorded in 6 patients (40%) – with 4 patients (27%) achieving a complete response and 2 (13%) achieving a partial response –, whereas 4 patients (27%) had stable disease and 5 had progressive disease. The median progression-free survival was 10 months (range 3–17), whereas the overall survival from the beginning of the chemotherapy was 19 months (range 1–30). Due to the small number of patients, no significant correlation with site of recurrence could be found. Conclusion: The combination of cisplatin and vinorelbine is a well-tolerated and active regimen in the treatment of patients with recurrent vulvar carcinoma.